Abstract: Recent advances in the understanding of the pathophysiology of ulcerative colitis (UC) have led to the expansion of our therapeutic arsenal. Conventional treatment options, including aminosalicylates, corticosteroids, thiopurines, and calcineurin inhibitors, fail to control the disease in a significant proportion of patients. Approximately 25-50% of the patients treated with tumor necrosis factor antibodies (anti-TNFα) are primary and secondary non-responders to therapy. Tofacitinib is a novel orally administered small synthetic molecule that inhibits a homologous family of enzymes, termed Janus kinases that modulate multiple key cytokines involved in the pathogenesis of UC. Phase II and III trials showed promising results in UC, leading the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to approve its administration for the induction and maintenance of remission in moderate-to-severe UC. Herein, we review tofacitinib for the management of UC, its mechanism of action pharmacokinetic properties, efficacy, and safety.
Introduction
Ulcerative colitis (UC) is an idiopathic immune-mediated inflammatory bowel disease of the colon. 1 It is often diagnosed in the third and fourth decades of life 2 and leads to significant mortality and morbidity. 3 Both UC and Crohn's disease are associated with economic impact from hospitalization and surgery and also loss of productivity at work. 3, 4 More than 80% of the UC patients run a relapsing disease course, whereas 10-15% experience an aggressive course. 5, 6 In 30% of the patients, the disease distribution is left-sided. Symptoms of UC include diarrhea, rectal bleeding, urgency, tenesmus, and fecal incontinence. Patients with UC are at risk of dysplasia and cancer. Between 10% and 15% undergo colectomy to manage disease or its complications.
with multiple different immune pathways involved in an individual resulting in a common phenotype -therefore, suppression of more than one cytokine pathway may be beneficial. Tofacitinib (XELJANZ/XELJANZ XR; Pfizer, NY, USA) is an oral small molecule pan-Janus kinase (JAK) inhibitor (molecular weight 312.4 Da; 504.5 for the citrate salt). This is the first oral formulation for the treatment of UC; tofacitinib is less immunogenic than the larger biologic antibodies, has a shorter half life, and has therefore got the advantage of allowing rapid discontinuation in cases of adverse events. 16 The JAKs are the downstream signaling molecules of a large number of the cytokine pathways involved in IBD. 17 When a cytokine binds its cell surface receptors, it dimerizes the ligand receptors and this results in phosphorylation of the JAK molecules. JAK then activates signal transducer and activator of transcription molecules (STATs), the phosphorylation of which results in STAT migration to the nucleus and activation of gene transcription. 17 By targeting JAK signaling, it is possible to affect multiple cytokine pathways thought to be involved in colitis. Tofacitinib had been initially approved for the treatment of moderate-to-severe rheumatoid arthritis (RA) [2012] and psoriatic arthritis (PsA) [2017] in adult patients with inadequate response or intolerance to prior disease-modifying antirheumatic drug therapies. 18 Phase II and phase III trials showed promising results in UC, leading the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to approve tofacitinib for the induction and maintenance of remission in moderate-to-severe UC. 19, 20 For induction, 10 mg is given orally twice daily for 8-week period, followed by a maintenance dose of 5 mg twice daily. 19, 20 Nevertheless, in case of inadequate response by week 8, the dose of 10 mg can be extended for another 8 weeks (16 weeks total) prior to attempting dose reduction or can be maintained at 10 mg in those patients who had previously failed anti-TNFα. 19 We review the pharmacokinetic properties, efficacy, and safety of tofacitinib in UC.
Search Strategy
Medline, PubMed, and Scopus search were undertaken by two of the authors (G.M and K.A). The search criteria used were "JAK inhibitor", "tofacitinib", "CP-690 550", "Ulcerative colitis", "pharmacokinetic", "side effects", "adverse events", and "complications". A manual search of the clinical trial register, article reference lists, abstracts from Digestive Disease Week, United European Gastroenterology Week, and European Crohn's Colitis Organization congresses were also conducted up to the 17th of May 2019. After an initial title screen, each relevant article was subsequently reviewed.
Overview of JAKs
JAKs compose a family of tyrosine kinases, that includes four large peptide members (≥1100 amino acids/molecular mass: 120-140 kilodaltons), named JAK 1, JAK 2, JAK 3, and Tyrosine Kinase 2 (TYK-2). Of the four family members, JAK1, JAK2, and TyK2 are ubiquitously expressed, whereas JAK3 is preferentially expressed in hematopoietic cells. 17, 21 All family members have an evolutionary con- Figure 1 .
JAKs regulate a variety of cytokine-mediated processes including hematopoiesis, inflammation, innate, and adaptive immunity. Aberrant activation of JAKs peptides has been shown to lead either directly or indirectly to a variety of autoimmune and inflammatory disorders, including UC. 23 Hence, it is of no surprise that the pharmacological inhibition of JAK has gained significant attention as a therapeutic target in immune-mediated disorders, with recent genomewide association studies supporting the rationale of targeting JAKs in UC. 23, 24 The JAK cytokines, however, are not responsible for all cytokine signaling. For example, TNFα mediates gene expression through the NF-kB, JUN kinase, p38 MAPK, and ERK1/ERK2 pathways. 
Pharmacokinetic Profile
The pharmacokinetic (PK) profile of tofacitinib has been studied in healthy volunteers and in patients with RA, PsA, and UC. In healthy volunteers, tofacitinib's time to serum peak concentrations is between 0.5 and 1 hrs, and it is eliminated in 3 hrs. No correlation was observed between dosage and lymphocyte subsets in healthy volunteers. 33 In UC, plasma tofacitinib concentrations increased proportionally with dose and steady-state levels did not change between baseline and 8 weeks. Steady-state concentrations did not differ according to disease activity 34 neither in UC nor in psoriatic arthropathy. 35 The majority (70%) of the drug is cleared by the liver, with 30% being renally excreted. 16 The clearance of tofacitinib is mediated by cytochrome P450 (CYP) 3A4; however, it does not affect the clearance of other drugs metabolized by CYP enzymes. 36 Use of other drugs that inhibit CYP 34A systems such as fluconazole and ketoconazole increased the half-life of tofacitinib by an hour. This would suggest that some dosage adjustment is required in the context of concomitant CYP34A inhibitor usage. 37 CrCl also affects the half-life of tofacitinib. 35 Population PK analysis from 1096 UC patients with moderate-to-severe disease activity, pooled across one phase 2 and three phase 3 studies, revealed comparable PK properties for tofacitinib with those observed in other immune-mediated conditions such as PsA and RA. Based on this comparability, all proposed dosing adjustment recommendations derived from phase 1 studies in RA are also applicable to UC patients. Consequently, in UC patients with moderate renal (defined as creatinine clearance values less than 60 mL/min), it is suggested to reduce to dose of tofacitinib by half. In contrast, no dose modification has been shown to be required for tofacitinib in association with a variety of other patientand disease-related factors including age, body weight, sex, ethnicity, and baseline disease severity (e.g., baseline Mayo score and baseline albumin). Tofacitinib has not been studied in the context of severe hepatic impairment. 19 
Therapeutic Efficacy of Tofacitinib in UC
A summary of the market-authorizing trials of tofacitinib's in UC included in this review is shown in Table 1 .
Phase II Studies
Sandborn et al investigated tofacitinib in a multi-center, double-blinded, randomized controlled trial over an 8-week period for moderate-to-severe UC. 38 Patients were assigned to placebo administered twice daily or tofacitinib (at doses of 0.5, 3 10, or 15 mg twice daily). The primary endpoint was clinical response (a decrease from baseline total Mayo score by at least 3 points and a relative decrease by at least 30%) at the end of the 8-week period. The secondary endpoint was clinical remission defined as a total Mayo score of 0 to 2. At 8 weeks, clinical response was observed in 32%, 48%, 61%, and 78% of the patients receiving tofacitinib at doses 0.5, 3, 10, and 15 mg BD, respectively (p values 0.39, 0.55, 0.10, and <0.001), compared with 42% of the patients receiving placebo. Endoscopic response was observed in 52%, 58%, 67%, and 78% of the patients on tofacitinib at doses of 0.5, 3, 10 and 15 mg BD, respectively, compared to 46% of the placebo (p values 0.64, 0.30, 0.07, and 0.001).
Although its highest efficacy was shown to be expected from doses ≥ 10 mg twice daily, safety concerns (dosedependent hyperlipidemia and viral infections) that have arisen from patients with RA receiving more than 15 mg BD 39 has led the FDA to select the 10 mg dose for the subsequent clinical development of tofacitinib in UC. 38 Efficacy in Phase III Trials
Induction of Remission and Mucosal Healing
The efficacy of tofacitinib in the induction of remission in patients with moderately-to-severely active UC was investigated in two multi-center, double-blind, placebocontrolled phase 3 trials, named OCTAVE (Oral Clinical Trials for tofAcitinib in ulceratiVE colitis) Induction 1 and 2. 40 In these trials, 1139 eligible patients were randomized (4:1) to receive tofacitinib 10 mg or placebo twice a day for an 8-week period. The patients had moderately-tosevere active (mean total Mayo score: 9) extensive colitis (52%) with a median disease duration of 6 years, mean age of 41years, with 59% of the participants being male and 80% caucasian. Approximately 70% of the patients had previously failed immunosuppressants other than biologic agents or corticosteroids, 52% had failed treatment with anti-TNFα (56% primary non-responders), and 46% were taking oral corticosteroids upon entry. Aminosalicylates or prednisolone up to 25 mg OD was allowed over the treatment period, but no immunomodulators or biologic therapies. The primary endpoint was clinical remission at 8 weeks (defined as a total Mayo score ≤2 points, no individual subscore >1, rectal bleeding subscore of 0). The key secondary endpoint was mucosal healing (MH defined as endoscopic subscore of 0 or 1) at 8 weeks. Clinical remission at 8 weeks occurred in 19% and 17% of the tofacitinib group, whereas the placebo groups had a remission rate of 8% and 4% in OCTAVE Induction 1 and 2, respectively (both comparisons were statistically significant). MH was achieved in 31% (OCTAVE 1) and 28% (OCTAVE 2) in tofacitinib versus 16% and 12% in those receiving placebo (p<0.001).
In both induction trials, subgroup analysis showed no significant differences in the efficacy of TOF over placebo for ethnic origin, previous experience to anti-TNFα and concomitant use of aminosalicylates. 40, 41 At all visits, patients receiving TOF had larger improvement in partial Mayo score compared to placebo with significant reductions in stool frequency. 42 
Maintenance of Remission and Mucosal Healing
A total of 593 patients from the OCTAVE Induction 1 or 2 trial who achieved clinical response at the end of 8 weeks with TOF 10 mg twice daily were re-randomized, in a 1:1:1 ratio into OCTAVE Sustain. These patients received maintenance therapy with tofacitinib 5 or 10 mg twice daily or placebo for 52 weeks. In this trial, 30% of the participants were in remission upon entry. The primary endpoint of OCTAVE Sustain was remission at 52 weeks. Key secondary endpoints were the achievement of MH at 52 weeks and of sustained glucocorticoid-free remission defined as glucocorticoid-free remission at 24 and 52 weeks. At 52 weeks, 34% of the 5 mg tofacitinib group, 41% in the tofacitinib 10 mg group, and 11% in the placebo group were in remission. As high as 37% in the patients receiving tofacitinib 5 mg, 46% of the tofacitinib receiving 10 mg, and in 13% of those receiving placebo had achieved MH. With regard to the other key efficacy endpoints, sustained and glucocorticoid-free remission were achieved by 35% and 47% of the 5-mg and 10-mg tofacitinib treatment arms as compared with the placebo arm, respectively (5%, p <0.001 for both comparisons). 40 In subsequent subgroup analysis, no significant differences in efficacy of tofacitinib over placebo with regard to patients' race and concomitant use of aminosalicylates 40, 41, 43 were noted. In addition, irrespective of the tofacitinib dose received or anti-TNFα failure status, patients who entered the trial in remission were more likely to remain in remission or MH at week 52, compared to those who had not achieved remission after induction. 44 At all visits, patients receiving tofacitinib had better improvements in the partial Mayo score as compared to those receiving placebo (p < 0.001 for all comparisons).
40,41

Long-Term Efficacy
The long-term efficacy of tofacitinib is being evaluated in an ongoing, open-label, long-term extension (OLE) study, named OCTAVE Open. In OCTAVE Open, all patients who had completed or experienced treatment failure in OCTAVE Sustain as well as non-responders to tofacitinib from OCTAVE Induction 1 and 2 were included ( Figure 2 ). The preliminary results of this study are summarized below.
Recapturing Response Loss of Response Secondary to Treatment Interruption
The effect of tofacitinib in recapturing response after treatment interruption was studied in a subpopulation of 101 patients entered into the OCTAVE Open trial. These patients had achieved clinical response with tofacitinib 10 mg twice daily in the OCTAVE Induction trials, but experienced treatment failure -loss of response -in the maintenance study after being randomized to receive placebo. Treatment failure was defined as increase ≥3 points from OCTAVE Sustain baseline total Mayo score plus increase in rectal bleeding subscore and endoscopic subscore ≥1 point and absolute endoscopic subscore ≥2 points after ≥8 weeks of maintenance therapy. All of these patients received tofacitinib 10mg twice daily in the OLE study. Study outcomes included clinical response, MH, and remission at months 2 and 12 of OCTAVE Open. At month 2, 76%, 55%, and 40% of the subpopulation achieved clinical response, MH and clinical remission, respectively. Similar findings were identified at 12 months in these key outcomes. Based on their findings, Panes et al suggested that in tofacitinib responders who lost response secondary to treatment interruption 
Maintenance of Remission Following Dose Reduction
The maintenance of remission for patients following a dose reduction in tofacitinib was investigated in a cohort of 76 patients from the SUSTAIN trial. 49 All of these patients were in remission at 52 weeks on tofacitinib 10 mg twice daily and subsequently received tofacitinib 5 mg twice daily in the OPEN study. Based on the time-point in the SUSTAIN trial that remission state was achieved, the patients were further divided into 3 groups. Patients who were in remission at baseline in the SUSTAIN trial were included in the first group (remission ≥12 months pre-dose reduction); patients in remission at 24 weeks were included in the second group (remission 6-<12 months pre-dose reduction); and patients in remission at 52 weeks were included in the third group (remission <6 months pre-dose reduction). Overall, rates for maintenance of remission were 82% at 12 months and 76% at 24 months in the OPEN study. Among the 3 different groups, the remission rates at 12 months were 91% for the first group, 82% for the second group, and 71% for the third group. This data suggest that the majority of UC patients who achieved stable remission with tofacitinib 10 mg twice daily and dose reduced to 5 mg twice daily maintained remission for up to 24 months Overall, tofacitinib was found to result in significant improvements in HRQoL compared to placebo, and this was strongly related to clinical and endoscopic remission. Similar conclusions were reached when data from the induction and maintenance trials were re-analyzed, using the comparatively more stringent IBDQ criteria for remission (total score ≥190) and response (≥30-point increase from baseline). 50 
Real-World Experience
The real-world experience of tofacitinib in the management of active UC derives from three retrospective studies from tertiary referral centers across USA and France (Table 2 ). Weisshof et al describe their experience of tofacitinib in a cohort of 58 patients with inflammatory bowel disease with UC, 4 with Crohn's disease, 1 with 
Comparative Efficacy of Tofacitinib vs Biological Therapies
In the absence of head-to-head trials, evidence of the comparative efficacy of tofacitinib and biological therapies is based on indirect evidence from four network metaanalyses (NMA). These all compared tofacitinib with antiTNFα (infliximab, adalimumab, golimumab) and antiintegrins (VDZ), and all synthesized data from randomized controlled phase II and/or III trials. Three out of four NMAs used clinical (response and remission) and endoscopic (MH) efficacy endpoints as outcomes, [54] [55] [56] whereas one used HRQoL. 57 Singh and Bonovas undertook their analyses of clinical and endoscopic endpoints in anti-TNFα naïve cohorts by basing their probabilities of each treatment being superior. The authors concluded that infliximab and VDZ may be superior for the induction of clinical response, remission, and MH. 58, 59 Trigo-Vicente et al reached similar
conclusions. 56 However, the addition of ozanimod (a sphingosine-1-phosphate receptor agonist) and etrolizumab (an anti-adhesion molecule antibody) in their analysis showed that ozanimod may be better than infliximab for the achievement of MH. In contrast, for patients who were anti-TNFα experienced, tofacitinib was ranked higher for the induction of remission and of MH compared to the other available treatments. 58 For the maintenance of remission, no indirect comparisons were performed for anti-TNFα experienced patients. [54] [55] [56] However, in anti-TNFα naïve patients, Trigo-Valente et al found that tofacitinib had the highest probability of being the best treatment in the maintenance of remission, sustained remission and for MH. With regard to the impact of different therapies on HRQoL, at induction, Paschos et al found that all of the compared therapies significantly improved both generic and disease-specific HRQL scores compared to placebo. 57 However, the improvement was clinically meaningful only for infliximab (18.58; 95% CI 13.19-23.97) and VDZ (18.00; 95% CI 11.08-24.92). For maintenance, VDZ, tofacitinib, and adalimumab were found to maintain the improvement in HRQL.
Safety of Tofacitinib in UC
The first centralized evaluation of the short-and long-term safety profile of tofacitinib in the management UC was recently published. 58 The report was focused on specific adverse events (AEs), including herpes zoster (HZ), opportunistic infections (OIs), malignancies, non-melanoma skin cancers (NMSC), major adverse cardiovascular events (MACE), and gastrointestinal perforations. The safety data were collated from the four aforementioned market-authorizing trials, including 1157 patients over a 4.4-year period (1612.8 patient-years of exposure). They were analyzed as 3 cohorts: the induction cohort, which included data from patients randomized to placebo or tofacitinib from the dose-finding phase II and the two phase III induction trials; the maintenance cohort, that included data from patients from the Sustain trial; and the laboratory cohort that included data from patients from the induction and the sustain cohort who were evaluated for changes over time in laboratory parameters. Serious adverse events (SAEs) were defined as any events threatening life, resulting in death, causing persistent or significant disability or incapacity, requiring or prolonging hospitalization, or causing congenital anomaly or birth defect.
In the induction cohort, 54.9% of the patients developed AEs and 3.8% developed SAEs resulting in tofacitinib being stopped. Similar rates were seen in patients receiving placebo, with AEs in 55.0% and SAEs in 5.0%. In contrast, higher rates of AEs (75.3%, 72.2%, and 79.6% for those receiving placebo, tofacitinib 5 mg, and 10 mg twice daily, respectively) and of SAEs (6.6%, 5.1%, and 5.6%) were found across all of the treatment arms in the maintenance cohort.
The most frequent adverse events seen in the induction cohort were headache (6.7% for placebo, 7.8% for tofacitinib 10 mg) and nasopharyngitis (5.0% for placebo, 6.0% for tofacitinib 10 mg), whereas nasopharyngitis (5.6% for placebo, 9.6% for tofacitinib 5 mg, 13.8% for tofacitinib 10 mg) and worsening of UC (35.9% for placebo, 18.2% for tofacitinib 5 mg, 14.8% for tofacitinib 10 mg) prevailed in the maintenance cohort. Serious infections (SI), defined as any treated infections that required parenteral antimicrobial therapy, hospitalization, or fulfilled criteria for SAEs, were rarely observed (IR: 2.0; 95% CI: 1.4-2.8). However, there were four types of SI that were reported more than once including appendicitis, herpes zoster infection (HZ), anal abscess, and Clostridium difficile infection. None of these infections were fatal.
In the maintenance cohort, the incidence ratio for HZ was found to be increased in UC, with greater values being observed in those patients receiving tofacitinib 10 mg compared to those receiving tofacitinib 5 mg or placebo. This finding signified a dose-proportional increase of the associated risk for HZ. In the overall cohort, there were recorded 18 cases of HZ, with older age, prior anti-TNFα failure, and non-white (mainly Asians) race being independently associated with an increased risk for developing HZ. However, in most cases, HZ infection was cutaneous over 1 or 2 adjacent dermatomes and did not require permanent discontinuation of tofacitinib. A more detailed analysis of HZ events in the UC program has been reported by Winthrop et al. 59 In this study, based on their previous experience in RA, the authors suggested that vaccination against HZ could be a possible preventive strategy for nonexposed UC patients; however, in the absence of robust data from UC, vaccination is not currently recommended. An ongoing randomized controlled trial evaluating the safety and immunogenicity of HZ vaccine across a variety of immune-mediated disorders, including patients with UC (VERVE trial, NCT02538341), 60 is expected to provide some more definitive results on this. During the observation period in the OCTAVE trials, four deaths were recorded in the overall population, with 3 out of 4 cases being secondary to malignancies (hepatic angiosarcoma, acute myeloid leukemia, and cholangiocarcinoma). In the overall cohort, 22 patients were diagnosed with malignancy, with 50% of the cases having NMSC. The majority (18 out of the 22) of patients were experienced with anti-TNFα and thiopurines, whereas 6 out of the 11 with NMSC had previous history of NMSC. Overall, malignancies were rarely observed.
With regard to other adverse events, 3 cases of colonic perforations and 4 MACEs (hemorrhagic stroke, aortic dissection, acute coronary syndrome, and myocardial infarction) were recorded in the study. Nearly all of the involved (5/7) patients had multiple risk factors that may have contributed to the development of these complications. In particular, 2 out of the 3 cases of perforation occurred in patients with a background of active UC inflammation or Epstein-Barr virus intestinal lymphoma who were recently prescribed corticosteroids and underwent an endoscopic procedure, whereas the third case occurred in a patient who developed appendicitis and received concomitant nonsteroidal anti-inflammatory drugs. Likewise, 3 out of 4 with MACE had ≥4 predisposing cardiovascular risk factors. However, other than a case of aortic dissection that resulted in death, all of the other MACE were resolved after temporary or permanent discontinuation of TOF.
No clinically meaningful changes were observed in various laboratory parameters, including the low-density lipoprotein/high-density lipoprotein ratio, hemoglobin, absolute lymphocyte count, and creatine kinase. 61 An update of the results of this study was presented by Sandborn et al in the most recent ECCO 2019 conference, extending our knowledge on the safety profile of tofacitinib by 1 year. 62 No additional or unexpected safety signals were identified, supporting the long-term use of tofacitinib in patients with moderately to severely active UC.
Safety of Tofacitinib vs Biological Therapies
As with comparisons of the efficacy between tofacitinib and biological therapy, comparative safety data are derived indirectly from NMAs. Trigo-Vicente et al showed that all comparative treatments were more likely to cause SAEs than placebo and that all therapies had similar probabilities of causing SAEs. 60 With regards to opportunistic infections, tofacitinib had the highest rate (although most were minor), whilst golimumab and vedolizumab also showed increased rates, and infliximab and adalimumab did not show a statistically significant increased rate compared to placebo.
Safety of Tofacitinib in Specific Populations
The safety of tofacitinib in children, pregnant women, and elder patients has not been directly studied in UC. However, Mahadevan et al recently reported pregnancy and infant outcomes from patients with both maternal and paternal prenatal exposure to tofacitinib who participated in the five aforementioned UC clinical trials. 63 Of the 1157 patients enrolled in these studies, 301 were women of childbearing age with 11 cases of maternal exposure and 14 cases of paternal exposure identified. In total, they reported 15 healthy newborns, no fetal or neonatal deaths, no congenital malformations, 2 spontaneous abortions, and 2 medical terminations. These findings appear similar to those reported from other clinical study populations and the general population. 64, 65 Nevertheless, more data are clearly needed to evaluate safety in this particular setting.
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Safety of Tofacitinib in Other Disease Populations
The incidence ratio of adverse events of special interest in the tofacitinib UC program was generally consistent with those reported in the RA program. However, a postmarketing study (A3921133) in RA found an increased incidence of pulmonary embolism among patients over 50 years with more than 1 cardiovascular factor receiving the 10 mg twice daily dose. This finding has led regulatory authorities to restrict the use of tofacitinib in patients with an increased risk for thromboembolism, which includes heart failure, cancer, thrombophilia, previous history of thromboembolic episodes, patients receiving hormonal contraceptives or hormone replacement therapy and those undergoing major surgery. 66 An ongoing safety trial in RA and future post-marketing studies in UC are expected to shed more light into this relationship.
Potential Place in UC Pharmacotherapy
Tofacitinib is the first oral JAK inhibitor that has been approved by the EMA and the FDA for the management of adult patients with moderately to severely active UC. The American College of Gastroenterology (ACG) has recently positioned tofacitinib in the therapeutic algorithm of UC either as first-line therapy for moderate-to-severely active disease or as second-line therapy in those who have failed anti-TNFα. 67 In addition, the real-world studies described above show that tofacitinib can be used effectively as third-line therapy in patients who have failed both anti-TNFα and vedolizumab. Although the NMAs suggest tofacitinib may be less effective than anti-TNFα as a firstline therapy and more effective as a second-line therapy, more substantial evidence is needed to inform selection preference.
As tofacitinib is the latest therapy to be approved for UC, its current use mostly assumes that of salvage therapy. However, compared to the available biologics (infliximab, adalimumab, golimumab, and VDZ), tofacitinib has several potentially favorable characteristics that could lead to its preferential selection. Firstly, it is orally administered which could improve therapy adherence and quality of life in patients averse to the requirement for long-term injections or infusions. 68, 69 Its pharmacokinetic profile, characterized by rapid absorption, metabolism, and clearance, is advantageous in situations where rapid onset of action (e.g., acute severe colitis) or elimination of the drug (e.g., infection, surgery, or pregnancy) is required. 70 Importantly, tofacitinib is a small synthetic molecule that would not induce an immunogenic response. Therefore, unlike the anti-TNFα in particular, there is no risk of loss of response due to antibody formation against the drug, negating the need for combination therapy with an immunomodulator to prevent this. 35 In addition, tofacitinib would be expected to have lower costs than the biologics, given it is a small molecule with less elaborate production and will therefore have a higher cost-effectiveness ratio.
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Future Directions
The evidence on the efficacy and safety of tofacitinib for the management of UC mainly arises from clinical trials and pertain to restricted populations. Post-marketing studies are needed to expand clinicians' experience on the efficacy and safety of tofacitinib in real-world populations, including specific groups excluded from the licensing trials (e.g., elders and children), and to address the potential thromboembolic risk highlighted in the RA population. With the approval of tofacitinib for the management of moderately-to-severely active UC, the available therapeutic options have increased, creating an issue with selection. Current evidence is insufficient to support preferential selection amongst the available therapeutic options and direct head-to-head comparison trials are necessary to address this issue. 74 
Conclusion
Tofacitinib is a valuable addition to the therapeutic armamentarium for managing UC. The OCTAVE trials have shown that tofacitinib is effective for the management of moderately-to-severely active UC with a good overall tolerance, although the potential risk of thromboembolism seen in the RA population needs further evaluation. Current recommendations issued by the ACG have positioned tofacitinib alongside the established biologic agents for both induction and maintenance of remission of moderate-to-severely active UC. Although tofacitinib possesses several favorable characteristics (e.g., oral administration, lack of immunogenicity, rapid action, and clearance), the exact place against more established biological therapies will become more evident as clinical experience with this novel agent improves. 
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